Align Technology, Inc.
ALGN Large CapHealthcare · Medical Instruments & Supplies
Updated: Jun 14, 2026, 22:19 UTC
Price Chart
Key Metrics
Valuation Analysis
About the Company
Align Technology, Inc. provides Invisalign clear aligners, Vivera retainers, and iTero intraoral scanners and services in the United States, Switzerland, and internationally. The company's Clear Aligner segment offers Invisalign comprehensive package to treat adults and teens malocclusion and features, and orthodontic needs of teenage or younger patients; and Invisalign First Phase I and Invisalign First Comprehensive Phase 2 package for younger patients between the ages of six and ten years with a mixture of primary/baby and permanent teeth. This segment also provides Invisalign express, Invisalign lite, and Invisalign moderate; Invisalign Go, Invisalign Go express, and Invisalign Go Plus; retention products, Invisalign training, adjusting tools used by dental professionals during treatme
Align Technology, Inc. Stock at a Glance
Align Technology, Inc. (ALGN) is currently trading at $174.84 with a market capitalization of $12.5B. The trailing P/E ratio stands at 29.43x, with a forward P/E of 14.13x. The 52-week range spans from $122.00 to $208.31; the current price is 16.1% below the yearly high. Year-over-year revenue growth stands at +6.2%. The net profit margin stands at 10.5%.
💰 Dividend
Align Technology, Inc. currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.
📊 Analyst Rating
14 analysts rate Align Technology, Inc. (ALGN) on consensus: Buy. The average price target is $209.07, implying +19.58% from the current price. Analyst price targets range from $175.00 to $240.00.
Align Technology, Inc.: The Investment Case in Detail
Align Technology, Inc. (ALGN) operates in the Healthcare — specifically Medical Instruments & Supplies — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.
The Bull Case
With a gross margin near 70.15%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns. Wall Street consensus sits at Buy with an average price target implying roughly 19.58% upside from current levels — analyst sentiment is firmly constructive.
Valuation in Context
With a PEG ratio of 0.92, the price-to-earnings multiple is actually below the company's growth rate — classic value-meets-growth territory that Peter Lynch would have called a 'GARP' opportunity.
What to Watch Next
- The forward P/E of 14.13x is meaningfully below the trailing 29.43x — analysts expect earnings to step up; the next earnings release is the test.
Investment Thesis: Strengths & Weaknesses
- High gross margin of 70.15% — indicates pricing power
- Analyst consensus: Buy
- Solid balance sheet with low debt (D/E 2.8)
- Positive free cash flow
No significant red flags in current metrics.
Technical Snapshot
Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).
Risk Profile
The data points to above-average price swings, elevated short interest (7.38%).
Trading Data
Related Stocks in the Same Sector
More Healthcare stocks
Top peers in the same sector — ranked by market cap.
Where can I buy Align Technology, Inc.?
Compare top-rated brokers — low fees, trusted providers, fully regulated.
Live Market Data
Real-time chart, financials, earnings, analysts, insider trades, events & news